Related Experiment Video
Updated: Feb 15, 2026

Colorimetric Analysis of Alkaline Phosphatase Activity in S. aureus Biofilm
Published on: April 12, 2019
Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe
Ming Chen1, Lixin Wan2,3, Jiangwen Zhang4
1Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Abstract:
The mitogen-activated protein kinase (MAPK) pathway is frequently aberrantly activated in advanced cancers, including metastatic prostate cancer (CaP). However, activating mutations or gene rearrangements among MAPK signaling components, such as Ras and Raf, are not always observed in cancers with hyperactivated MAPK. The mechanisms underlying MAPK activation in these cancers remain largely elusive. Here we discover that genomic amplification of the PPP1CA gene is highly enriched in metastatic human CaP. We further identify an S6K/PP1α/B-Raf signaling pathway leading to activation of MAPK signaling that is antagonized by the PML tumor suppressor. Mechanistically, we find that PP1α acts as a B-Raf activating phosphatase and that PML suppresses MAPK activation by sequestering PP1α into PML nuclear bodies, hence repressing S6K-dependent PP1α phosphorylation, 14-3-3 binding and cytoplasmic accumulation. Our findings therefore reveal a PP1α/PML molecular network that is genetically altered in human cancer towards aberrant MAPK activation, with important therapeutic implications.
Insights
Genomic amplification of PPP1CA gene drives metastatic prostate cancer by activating the MAPK pathway. The PML tumor suppressor counteracts this by sequestering PP1α, revealing a key cancer-driving molecular network.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Mitogen-activated protein kinase (MAPK) pathway hyperactivation is common in advanced cancers like metastatic prostate cancer (CaP).
- Mechanisms of MAPK activation in cancers lacking Ras/Raf mutations are not fully understood.
- Genomic alterations in MAPK pathway components are not always the cause of its aberrant activation.
Purpose of the Study:
- To investigate novel mechanisms of MAPK pathway activation in metastatic prostate cancer.
- To identify genetic alterations and signaling pathways contributing to MAPK hyperactivation.
- To elucidate the role of the PML tumor suppressor in regulating MAPK signaling.
Main Methods:
- Genomic analysis to identify enriched gene amplifications in metastatic CaP.
- Signal transduction pathway analysis involving S6K, PP1α, B-Raf, and MAPK.
- Investigation of protein-protein interactions and subcellular localization (PML nuclear bodies).
Main Results:
- Genomic amplification of the PPP1CA gene is significantly enriched in metastatic human CaP.
- An S6K/PP1α/B-Raf signaling cascade was identified, leading to MAPK activation.
- PML tumor suppressor antagonizes MAPK activation by sequestering PP1α in nuclear bodies, preventing its activation.
Conclusions:
- PP1α acts as a B-Raf activating phosphatase, crucial for MAPK pathway activation.
- PML suppresses MAPK signaling by inhibiting PP1α phosphorylation and cytoplasmic accumulation.
- The PP1α/PML molecular network is a novel, genetically altered pathway in cancer, offering therapeutic targets.
More Related Videos
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
tRNA Activation
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
Co-activators and Co-repressors
Activation Energy

